Short Report of a Phase II Trial of Nintedanib in Recurrent Malignant Pleural Mesothelioma (MPM). Wozniak AJ, Schneider B, Kalemkerian GP, Daly B, et al. Clin Lung Cancer 2023;24:563-567.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Wozniak AJ, Schneider B, Kalemkerian GP, Daly B, et al. Short Report of a Phase II Trial of Nintedanib in Recurrent Malignant Pleural Mesothelioma (MPM). Clin Lung Cancer 2023;24:563-567.
PMID: 37301693